Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which ...

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

C3.ai(NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

C3.ai, Inc. (AI) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.

To get a sense of who is truly in control of C3.ai, Inc. , it is important to understand the ownership structure of the business. We can see that institutions own the lion's share ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Detailed price information for Palantir Technologies Inc Cl A (PLTR-Q) from The Globe and Mail including charting and trades.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of C3.ai's market ...

Artificial intelligence companies are largely cheering President Trump’s “AI Action Plan” issued this week — no surprise, ...

Cobalt prices are steady as Congo extends its export ban. Explore mining updates, major project milestones, and industry ...